REZOLUTE, INC. Debt Instrument, Periodic Payment, Principal
REZOLUTE, INC. (RZLT) reported Debt Instrument, Periodic Payment, Principal of $5.34 million for the 12-month period ending 2020-06-30, per its 10-K filed 2020-10-13.
Discontinued › Notes › Debt › Debt Instruments › Debt Instrument, Periodic Payment
us-gaap:DebtInstrumentPeriodicPaymentPrincipal · last filed 2020-10-13
- REZOLUTE, INC. debt instrument, periodic payment, principal for the quarter ending 2019-06-30 was $0.00.
- REZOLUTE, INC. debt instrument, periodic payment, principal for the quarter ending 2019-03-31 was -$10.00K.
- REZOLUTE, INC. debt instrument, periodic payment, principal for fiscal 2020 was $5.34M, a 0.00% change from fiscal 2019.
- REZOLUTE, INC. debt instrument, periodic payment, principal for fiscal 2019 was $5.34M.
| Period end | Debt Instrument, Periodic Payment, Principal 1 month | Debt Instrument, Periodic Payment, Principal 3 month | Debt Instrument, Periodic Payment, Principal 6 month | Debt Instrument, Periodic Payment, Principal 9 month | Debt Instrument, Periodic Payment, Principal 12 month |
|---|---|---|---|---|---|
| 2020-06-30 | $5.34M 10-K · filed 2020-10-13 | ||||
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-10 | -$10.00K derived: sum of 2 quarters · filed 2019-09-10 | $5.34M 10-K · filed 2019-09-10 | ||
| 2019-03-31 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-10 | $5.34M 10-Q · filed 2019-05-10 | |||
| 2019-01-30 | $5.34M 10-Q · filed 2019-05-10 | ||||
| 2018-12-31 | $5.35M 10-Q · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |